PMH 9907: Long ‐term outcomes of a randomized phase 3 study of short‐term bicalutamide hormone therapy and dose‐escalated external‐beam radiation therapy for localized prostate cancer
CONCLUSIONSFor patients who predominantly have IRPC, the addition of HT to DE‐EBRT did not significantly affect BF, OS, or LC. Bicalutamide appeared to be well tolerated. The conclusions from the study are limited by incomplete recruitment. Cancer 2016;122:2595–603. © 2016 American Cancer Society.
Neoadjuvant hormone therapy (NHT) when given to men receiving radiation therapy (RT) for prostate cancer is known to affect long term testosterone (T) levels. Men with suppressed T may experience a lower PSA value which could influence biochemical failure determinations. We sought to determine which factors influenced the last measured T and PSA values and the relationship between the two.
To determine the influence of neoadjuvant hormone therapy (NHT) and testosterone level (T) on all cause survival (ACS) following prostate seed implantation (PSI).
Degarelix has been reported to offer superior control of lower urinary tract symptoms (LUTS) compared to luteinizing hormone-releasing hormone (LHRH) agonist. However, whether degarelix can reduce acute genitourinary toxicity associated with irradiation when used as neoadjuvant androgen-deprivation therapy (ADT) remains unclear. The aim of this study was to evaluate the efficacy of degarelix as neoadjuvant ADT followed by radiation therapy in the control of acute genitourinary toxicity compared to LHRH agonist.
CONCLUSIONS: External beam radiation therapy with N-HT was associated with improved overall survival compared to C-HT. This study is hypothesis-generating and further studies are needed to best qualify the sequencing of hormone therapy with the duration of treatment. PMID: 28085179 [PubMed - as supplied by publisher]
Authors: Evangelista L, Zattoni F, Guttilla A, Basso U, Zattoni F Abstract BACKGROUND: To evaluate how neoadjuvant androgen deprivation therapy (ADT) can impact 18F- Choline uptake in primary prostate cancer (PC) and its metastases before radical prostatectomy (RP) or radiation therapy (RT). METHODS: We retrospectively reviewed images of 79 PC patients undergoing 18F-Choline PET/CT before RP or RT. Based on concomitant administration of neoadjuvant ADT at the time of 18F-Choline PET/CT, patients were subdivided into naïve group (Group 1) and neoadjuvant ADT group (Group 2). PET/CT results, SUVmax and metab...
1551Objectives To evaluate how adjuvant therapy (ADT) can impact on 18F-Choline uptake in primary prostate cancer (PC) and its metastases before radical prostatectomy (RP) or radiation therapy (RT).Methods We retrospectively revised images of 79 PC patients undergoing 18F-Choline PET/CT before RP or RT. In according to the concomitant administration of neoadjuvant ADT at the time of 18F-Choline PET/CT, the patients were subdivided in two main groups (without and with neoadjuvant ADT, named Group 1 and Group 2). PET/CT results and SUVmax for each positive site were re-assessed by a dedicated uro-radiologist with more than 5...
CONCLUSIONSFor patients who predominantly have IRPC, the addition of HT to DE‐EBRT did not significantly affect BF, OS, or LC. Bicalutamide appeared to be well tolerated. The conclusions from the study are limited by incomplete recruitment. Cancer 2016. © 2016 American Cancer Society.
Based on the results of several randomized phase III trials [1–4], the combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) has become the current standard of care for men with locally advanced prostate cancer (PCa). Neoadjuvant ADT (nADT) before radiotherapy (RT) and also concomitant and adjuvant ADT for various lengths of time has been used in most of these studies. According to the National Comprehensive Cancer Network (NCCN) guidelines, patients with intermediate-risk PCa may be treated with a combined treatment modality including 4 to 6 months of ADT [2,5–10], wherea...
To determine whether participants taking angiotensin-converting enzyme inhibitors (ACEIs) and treated with radical radiation therapy with neoadjuvant/adjuvant hormone therapy have less incidence, severity, and duration of radiation proctitis.
To investigate a possible detrimental role of neoadjuvant hormonal therapy (NEOHT) prior to radical prostatctomy (RP) in a cohort of 513 node-negative patients (pts) treated with RP and adjuvant radiotherapy (ART) followed for more than 10 years.